These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 23528382)

  • 1. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
    Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
    Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
    Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
    Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and
    Altai M; Westerlund K; Velletta J; Mitran B; Honarvar H; Karlström AE
    Nucl Med Biol; 2017 Nov; 54():1-9. PubMed ID: 28810153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
    Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
    Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel
    Liu Y; Oroujeni M; Liao Y; Vorobyeva A; Bodenko V; Orlova A; Konijnenberg M; Carlqvist M; Wahlberg E; Loftenius A; Frejd FY; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39008065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionuclide Therapy of HER2-Expressing Xenografts Using [
    Liu Y; Xu T; Vorobyeva A; Loftenius A; Bodenko V; Orlova A; Frejd FY; Tolmachev V
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173878
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.